UPDATE: Valeant Pharmaceuticals (VRX) PT Lowered to $19 at BMO Capital Following 4Q Results; 'Entering Transitional Period'
Tweet Send to a Friend
(Updated - March 1, 2017 6:19 AM EST)
BMO Capital analyst Gary Nachman lowered its price target on Valeant ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BMO Capital analyst Gary Nachman lowered its price target on Valeant ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
